Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
RESEARCH TOOLSreports
Holding JANX?
Track your performance easily
JANX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.79 - $71.71
Previous CloseN/A
Volume1.13M
Average Volume (3M)1.45M
Market Cap
$2.35B
Enterprise Value$1.85B
Total Cash (Recent Filing)$658.00K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.73
Next Earnings
Mar 07, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding57,799,480
10 Day Avg. Volume1,278,966
30 Day Avg. Volume1,447,843
Standard Deviation0.76
R-Squared0.04
Alpha0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)176.68
Price to Cash Flow (P/CF)-258.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue141.56
Enterprise Value/Gross Profit228.53
Enterprise Value/Ebitda-27.80
Forecast
1Y Price Target
$92.00Price Target Upside126.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Janux Therapeutics Inc News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyJANX007 demonstrated impressive, best-in-disease PSA efficacy and a best-in-class, differentiated safety profile across all evaluable patients with metastatic castration-resistant prostate cancer.
Financial OutlookA strong cash position with approximately $658 million suggests financial stability for future developments.
Technological AdvancementsThe best-in-class masking technology platform used by Janux shows a positive readthrough to other pipeline assets.
Bears Say
Clinical RisksJANX007 clinical risks are the most significant to the Outperform rating and price target.
Competitive PressureVir Biotechnology's data highlight increasing interest and advancements in conditionally active T cell engagers, putting competitive pressure on JANX.
Financial PerformanceThe company reported total revenues of approximately $0.44M and a net loss of $0.51 per share, compared to the consensus estimates of total revenues of $0.77M and a net loss of $0.35 per share.
---
Ownership Overview
55.01% Insiders
16.40% Mutual Funds
<0.01% Other Institutional Investors
20.76% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $7.79 and its highest was $71.71 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Janux Therapeutics Inc’s market cap is $2.35B.
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is Mar 07, 2025 which is in 48 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Nov 06, 2024. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.327 by -$0.183.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -0.44.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 57,799,480 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.327. Following the earnings report the stock price went down -1.239%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Currently, no hedge funds are holding shares in JANX
---
Janux Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.00 (126.55% Upside)
$92.00 (126.55% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
319.09%
12-Months-Change
Fundamentals
Return on Equity
-12.05%
Trailing 12-Months
Asset Growth
79.66%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
---
JANX Stock 12 Month Forecast
Average Price Target
$92.00
▲(126.55% Upside)
Technical Analysis
Nurix Therapeutics
―
RAPT Therapeutics
―
Bicycle Therapeutics
―
Fulcrum Therapeutics
―
Prelude Therapeutics
―
Bolt Biotherapeutics
―
Best Analysts Covering JANX
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+93.11%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +93.11% per trade.
---